4/312017 (cid:9)
`
`BIG plc I BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology
`
`6
`
`BTG BTG
`Imagine where we can go.
`
`BTG Licenses New Prostate Cancer Drug
`to Cougar Biotechnology
`20 April 2004
`London, UK, April 20, 2004 - BTG (LSE: BGC), the global technology commercialisation company and Los Angeles-based
`Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide
`exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced
`prostate cancer. BTG will receive an upfront cash payment and will benefit from further development milestones and a
`royalty on sales. Detailed financial terms were not disclosed.
`
`Abiraterone was first synthesised at The Institute of Cancer Research (ICR) in the UK as part of a BTG-funded programme
`to discover a potent, selective, orally active drug to inhibit the key enzyme in testosterone synthesis,
`17ahydroxylase/C1720-lyase. Suppression of testosterone synthesis was subsequently demonstrated in patients with
`prostate cancer.
`
`Dr Roger Harrison, Vice President and Director of BTG’s Oncology Business Unit said, "We are very pleased to have
`secured a licensing partner with such a clear vision for the development and future clinical application of abiraterone acetate.
`This deal shows the value that we create for our partners, like ICR, and confirms that BTG is an important source of
`exciting new cancer drugs for the pharmaceutical industry."
`
`Dr. Ane Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology said, "There is an urgent
`need for new and effective therapies for patients with advanced prostate cancer who fail first-line hormonal treatment. We
`believe that abiraterone could fill this void and serve as an important second-line hormonal agent."
`
`Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added "We are pleased to be able to
`complete this licensing agreement with BTG for this novel, targeted therapy. We look forward to advancing the development
`of abiraterone during 2004."
`
`In the US, prostate cancer is the second leading cause of cancer death in men. Approximately one in six American men will
`develop prostate cancer at some time during their lifetime, and there are approximately 220,900 new cases each year. In the
`US, the annual death toll from prostate cancer is 28,900. The incidence of prostate cancer in the EU is approximately
`142,000 and some 59,700 men die of the disease.
`
`About BTG
`BTG finds, develops and commercialises emerging technologies in the life and physical sciences. These innovations are
`protected by a strong portfolio of intellectual property that BTG develops and enhances. BTG then captures the value in
`these technologies through licensing and venturing activities. From the origins of its business in 1949, BTG has
`commercialised major innovations such as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting protein,
`Campathfi (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is quoted on the London Stock Exchange under the
`symbol "BGC" and operates from offices in London and Philadelphia, with representation in Tokyo. BTG operates through
`wholly owned subsidiaries, BTG International Ltd and BTG International Inc in the UK and USA, respectively. Further
`information about BTG can be found at www.btcn3lc.com .
`
`About Cougar Biotechnology
`Cougar Biotechnology, Inc. is a Los Angeles based private biotechnology company, established to in-license and develop
`early clinical stage drugs, with a specific focus on the field of oncology. Further information about Cougar Biotechnology can
`be found at www.cougarbiotechnoIogy.com .
`
`https://www.btgpl c.com/medi a/press-releases/btg-1 I censes-new-prostate-cancer-drug-to-cougar-bi otechnol ogy/ (cid:9)
`
`1/2
`
`WCK1087
`Wockhardt Bio AG v. Janssen Oncology, Inc.
`IPR2016-01582
`
`1
`
`
`
`BIG plc I BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology
`
`6
`
`BTG BTG
`Imagine where we can go.
`
`BTG Licenses New Prostate Cancer Drug
`to Cougar Biotechnology
`20 April 2004
`London, UK, April 20, 2004 - BTG (LSE: BGC), the global technology commercialisation company and Los Angeles-based
`Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide
`exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced
`prostate cancer. BTG will receive an upfront cash payment and will benefit from further development milestones and a
`royalty on sales. Detailed financial terms were not disclosed.
`
`Abiraterone was first synthesised at The Institute of Cancer Research (ICR) in the UK as part of a BTG-funded programme
`to discover a potent, selective, orally active drug to inhibit the key enzyme in testosterone synthesis,
`17ahydroxylase/C1720-lyase. Suppression of testosterone synthesis was subsequently demonstrated in patients with
`prostate cancer.
`
`Dr Roger Harrison, Vice President and Director of BTG’s Oncology Business Unit said, "We are very pleased to have
`secured a licensing partner with such a clear vision for the development and future clinical application of abiraterone acetate.
`This deal shows the value that we create for our partners, like ICR, and confirms that BTG is an important source of
`exciting new cancer drugs for the pharmaceutical industry."
`
`Dr. Ane Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology said, "There is an urgent
`need for new and effective therapies for patients with advanced prostate cancer who fail first-line hormonal treatment. We
`believe that abiraterone could fill this void and serve as an important second-line hormonal agent."
`
`Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added "We are pleased to be able to
`complete this licensing agreement with BTG for this novel, targeted therapy. We look forward to advancing the development
`of abiraterone during 2004."
`
`In the US, prostate cancer is the second leading cause of cancer death in men. Approximately one in six American men will
`develop prostate cancer at some time during their lifetime, and there are approximately 220,900 new cases each year. In the
`US, the annual death toll from prostate cancer is 28,900. The incidence of prostate cancer in the EU is approximately
`142,000 and some 59,700 men die of the disease.
`
`About BTG
`BTG finds, develops and commercialises emerging technologies in the life and physical sciences. These innovations are
`protected by a strong portfolio of intellectual property that BTG develops and enhances. BTG then captures the value in
`these technologies through licensing and venturing activities. From the origins of its business in 1949, BTG has
`commercialised major innovations such as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting protein,
`Campathfi (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is quoted on the London Stock Exchange under the
`symbol "BGC" and operates from offices in London and Philadelphia, with representation in Tokyo. BTG operates through
`wholly owned subsidiaries, BTG International Ltd and BTG International Inc in the UK and USA, respectively. Further
`information about BTG can be found at www.btcn3lc.com .
`
`About Cougar Biotechnology
`Cougar Biotechnology, Inc. is a Los Angeles based private biotechnology company, established to in-license and develop
`early clinical stage drugs, with a specific focus on the field of oncology. Further information about Cougar Biotechnology can
`be found at www.cougarbiotechnoIogy.com .
`
`https://www.btgpl c.com/medi a/press-releases/btg-1 I censes-new-prostate-cancer-drug-to-cougar-bi otechnol ogy/ (cid:9)
`
`1/2
`
`WCK1087
`Wockhardt Bio AG v. Janssen Oncology, Inc.
`IPR2016-01582
`
`1
`
`
`
`4/3/2017 (cid:9)
`
`BTG plc I BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology
`About The Institute of Cancer Research
`The Institute of Cancer Research is one of the worlds leading cancer research organisations and is internationally renowned
`for the quality of its science. The Institute was founded in 1909 to investigate the causes of cancer and develop new
`strategies for its prevention, diagnosis, treatment and cure. Its mission is the relief of human suffering by pursuing
`excellence in the fight against cancer. The Institute is a College of the University of London and works in a unique
`partnership with The Royal Marsden Hospital. Together they form Europe’s largest comprehensive cancer centre. The
`Institute is a charity that relies on voluntary income. Further information about The Institute of Cancer Research can be
`found at www.icr.ac.uk .
`
`Contact
`Lorraine Jones, BIG
`+44 (0)20 7575 1622
`lorraine.iones (@btaK)lc.com
`
`Alan H. Auerbach, Cougar Biotechnology, Inc.
`+1 310 443 4209
`ahauerbach( couparbiotechnology. corn
`
`Marie MacLean, Press Officer
`Institute of Cancer Research
`+44 (0)20 7153 5359
`marie. macleanicr. ac. uk
`
`UI
`
`Back to press releases
`
`At BTG we are focused on developing innovative products in specialist areas of medicine to better serve doctors and patients.
`
`' 2016 BTG International Ltd. All rights reserved. "See More, Reach Further, Treat Smarter", "Imagine where we can go", and BIG and the BTG roundel logo are trademarks
`
`of BIG International Ltd. BIG and the BTG roundel logo are registered trademarks of BTG International Ltd in the US, EU and certain other territories. Bead Block, DC Bead,
`
`DC Bead LUMI, LC Bead and LC Bead LUMI are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS and EkoSonic are registered trademarks of
`
`EKOS Corporation. GALIL is a trademark of Galil Medical Ltd. PneumRx is a registered trademark of PneumRx, Inc. IheraSphere is a registered trademark of Theragenics
`
`Corporation used under license by Biocompatibles UK Ltd. Varithena is a registered trademark of Provensis Ltd. CroFab and DigiFab are registered trademarks of BTG
`
`International Inc. Vistogard is a registered trademark of Wellstat Therapeutics Corporation. Voraxaze is a registered trademark of Prothencs Medicines Development Ltd.
`
`Lemtrada is a trademark of Genzyme Corporation. Zytiga is a trademark of Johnson & Johnson. Biocompatibles UK Ltd, EKOS Corporation, Gall Medical Lid, PneumRx,
`
`Inc., Protherics Medicines Development Ltd, and Provensis Ltd are all BIG International group companies. Not all products and/or indications are available in all territories.
`For prescribing information, safety information, and/or product information, go to: bead-block.com crofab.com I dcbead.com I dcbeadlumi.com I digifsb.us I ekoscorc.com I
`ctalilmedical,corn I lcbead.com I Icbeadlumi.com I Iemtrada.com I pneumrx.com I therasphere.com I varithena.com I vistogard.com I voraxaze.com I zytipa.com
`
`ogy/ (cid:9)
`
`2/2
`
`2
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
